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The hyperparathyroidism-jaw tumour (HPT-JT)
syndrome is an autosomal dominant disorder
characterized by parathyroid tumours, which are
frequently carcinomas, and ossifying jaw fibromas.
In addition, some patients may develop renal
tumours and cysts. The gene causing HPT-JT,
which is referred to as HRPT2 and is located on
chromosome 1q31.2, encodes a 531 amino acid
protein called PARAFIBROMIN. To date 42 muta-
tions, of which 22 are germline, have been
reported and 97% of these are inactivating and
consistent with a tumour suppressor role for
HRPT2. We have investigated another four HPT-JT
families for germline mutations, searched for
additional clinical phenotypes, and examined for a
genotype–phenotype correlation. Mutations were
found in two families. One family had a novel
deletional-insertion at codon 669, and the other
had a 2 bp insertion at codon 679, which has
been reported in four other unrelated patients.
These five unrelated patients and their families
with the same mutation were not found to develop
the same tumours, thereby indicating an absence
of a genotype–phenotype correlation. An analysis
of 33 HPT-JT kindreds revealed that affected
women in 13 HPT-JT families suffered from
menorrhagia in their second to fourth decades.
This often required hysterectomy, which revealed
the presence of uterine tumours. This resulted in a
significantly reduced maternal transmission of the
disease. Thus, the results of our analysis expand
the spectrum of HPT-JT-associated tumours to
include uterine tumours, and these may account*These authors contributed equally to this work.
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for the decreased reproductive fitness in females
from HPT-JT families.
Keywords: bone tumours, HRPT2 mutations,
kidney cysts, parathyroid cancer.
Introduction
The hyperparathyroidism-jaw tumour syndrome
(HPT-JT) is an autosomal dominant disorder char-
acterized primarily by parathyroid tumours in
association with maxillary and/or mandibular ossi-
fying fibromas [1–5]. Parathyroid tumours, detected
by hypercalcaemia, occur in approximately 90% of
HPT-JT patients and are usually the first manifesta-
tion of the disease [6]. The underlying aetiology is
usually a solitary parathyroid adenoma [6] but
multigland disease may also occur and the fre-
quency of parathyroid carcinoma in HPT-JT is
approximately 15% [7]. These features result in
recurrent parathyroid disease, which is common in
HPT-JT. The prevalence of ossifying fibromas of the
jaw is approximately 35% in HPT-JT patients and
these may appear as early as 13 years of age [5].
The ossifying fibromas are histologically different
from the osteoclastic ‘brown’ tumours of primary
hyperparathyroidism and do not regress following
curative parathyroid surgery [1, 5]. Some HPT-JT
patients may also develop renal abnormalities,
which include hamartomas, polycystic disease and
Wilms’ tumours [2–5, 8, 9]. Other tumours, inclu-
ding Hurtle cell thyroid adenomas, pancreatic
adenocarcinomas and testicular mixed germ cell
tumours, have also been observed in one or two
patients with HPT-JT [9]. It is important to note that
in some kindreds, parathyroid tumours may be the
sole disease manifestation and this has been referred
to as familial isolated hyperparathyroidism (FIHP)
[4, 10–12]. However, it is also important to note
that germline mutations in other genes are more
frequently involved in FIHP [13, 14].
The gene causing HPT-JT, which is referred to as
HRPT2, is located on chromosome 1q31.2 and
consists of 17 exons (Fig. 1) that span 1.3 Mb of
genomic DNA [15]. The HRPT2 gene has two
transcripts; one of 2.7 kb which encodes a ubiqui-
tously expressed and evolutionarily conserved 531
amino acid protein named PARAFIBROMIN and the
other of 4.4 kb which has not yet been characterized
[15]. PARAFIBROMIN has two putative nuclear
localization sequences (NLSs) and, given its partial
homology to the yeast protein Cdc73p [15], it seems
likely that it may act as a transcription factor.
However, the role of PARAFIBROMIN in normal
cellular function is unknown and the mechanisms
by which its abnormalities lead to tumours of the
HPT-JT syndrome, remain to be elucidated [15]. To
date 18 different heterozygous germline HRPT2
mutations have been reported in HPT-JT and FIHP
(Table 1, Fig. 1) [13, 15–18]. In addition, a total of
14 somatic mutations (Fig. 1) have been identified
from analysis of parathyroid tumour DNA [13,
15–17]. The mutations are scattered throughout the
coding region (Fig. 1), although currently no muta-
tions have been reported in exons 6, 9–13 and
15–17. Exons 1, 2 and 7 are more frequently
involved and contain 38%, 17% and 21%, respect-
ively of the mutations. The over-representation of
mutations in these three exons is not due to their
larger sizes, as an examination of exons 8, 14, 15
and 16, which are of similar sizes, reveals these to
contain between 0 and 7% of all mutations (Fig. 1).
Over 97% of the mutations found in germline DNA
and in somatic DNA of tumours, are nonsense or
frameshift mutations that are predicted to result in a
functional loss of the PARAFIBROMIN protein
because of premature truncation. Two missense
germline mutations have been reported, one of
which affects the initiation methionine (family K1,
Table 1) and the second alters an evolutionarily
conserved leucine to a proline (family K9, Table 1).
Proline is known to be a helix breaker [19] and is
likely, therefore, to affect the function of PARAFI-
BROMIN by disrupting its tertiary structure. Both
the observation of loss of heterozygosity (LOH)
involving this region of chromosome 1q in some
HPT-JT tumours [3–5, 9] and the inactivating
germline and somatic mutations found in patients,
suggest that the HRPT2 gene acts as a tumour
suppressor consistent with the Knudson ‘two-hit’
model for hereditary cancer [20]. This has been
supported by the identification of the combined
occurrence of a somatic and germline HRPT2
mutation in a single parathyroid carcinoma from a
HPT-JT patient [16]. HRPT2 mutations do not seem
to be common in sporadic parathyroid adenomas
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[15, 16] but two studies [16, 17] have reported a
high frequency of HRPT2 mutations in sporadic
parathyroid carcinomas (67–100%), thereby indi-
cating an important role for this gene in malignant
transformation of the parathyroid. In addition, one
of these studies unexpectedly identified germline
HRPT2 mutations (Fig. 1) in three patients with
sporadic parathyroid carcinomas [17]. These find-
ings indicate that patients with parathyroid carci-
nomas or their relatives should be clinically assessed
for HPT-JT-associated tumours and offered muta-
tional analysis with genetic counselling.
In order to further characterize abnormalities
associated with this recently identified gene and
determine the spectrum of phenotypic manifestations
in this disorder, we undertook mutational analysis in
four HPT-JT families, and searched for genotype–
phenotype correlations and additional phenotypic
features. We particularly inquired for gynaecological
abnormalities, as we had noticed that five of seven
affected women in two previously reported HPT-JT
kindreds (families K7 and K31, Tables 1 and 2) [8]
did not have offspring, and anecdotal information
suggested that women with HPT-JT had developed
menstrual irregularities that required hysterectomy
at a young age.
Materials and methods
Patients and families
Four HPT-JT kindreds (families K14, K18, K32 and
K33, Tables 1 and 2) were ascertained. Family K14
was previously reported as a brother and sister
with parathyroid cancers, which were excised with
a recurrence in the sister, and other family
members were subsequently discovered to have
parathyroid tumours [21]. Family K18 was
previously reported as having FIHP caused by
solitary adenomas and subsequent observations of
multiple adenomas in an affected member have
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Fig. 1 Schematic representation of the genomic organization of the HRPT2 gene and its pathological mutations. The human HRPT2 gene
spans 1.3 Mb of genomic DNA and encodes a 531 amino acid protein, called PARAFIBROMIN [15]. The 1593 bp coding region is
organized into 17 exons (sizes indicated) and 16 introns. The 5¢-part of exon 1 and the 3¢-part of exon 17 are untranslated (hatched boxes).
The start (ATG) and stop (TGA) sites, in exons 1 and 17 respectively, are indicated. The locations of the two putative nuclear localization
signals (NLSs), which lie between codons 76–93 and 393–409 respectively, are represented by thick horizontal lines. The 44
mutations reported [2, 5, 8, 10, 13, 15, 16, 18, 21–23] in the HRPT2 gene are shown; these include 10 nonsense (red lines), two missense
(blue lines) and 32 frameshift (green lines) mutations. The 24 germline mutations are indicated by solid lines, 14 somatic mutations
by short dashed lines and the six mutations where the status is unknown (u) by long dashed lines. The two new mutations, detected in
kindreds K14 and K18 (Table 1) are identified with an asterisk. Exons 1, 2 and 7 have significantly more mutations than the other
exons, and harbour 38%, 17% and 21%, respectively of the mutations. This is further illustrated by an examination of exons 8, 14, 15
and 16, which are of a similar size, and which harbour fewer mutations in the range of 0–7%. Indeed, the mutation number per 100 bp
of DNA sequence for exons 1, 2 and 7, are 12, 7 and 5, respectively, and these are significantly higher (P < 0.01 for exon 1 and
P < 0.05 for exons 2 and 7) when compared with the other exons. Thus, the over-representation of mutations in exons 1, 2 and 7 is not a
function of their larger sizes.
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members and family K33 contained three affected
members. The clinical and genetic data from these
four families were pooled with the published and
unpublished data from 29 families (Tables 1 and 2)
[1, 2, 5, 8, 10, 13, 15, 16, 18, 21–27] for analysis
of genotype–phenotype correlations. Anecdotal
information that many young women with HPT-
JT had required hysterectomy led to more detailed
inquiries for menstrual history and uterine surgery
in females from 13 of these families that were
available for study.
Mutational analysis
Venous blood samples were obtained from the
patients according to guidelines approved by the local
ethical board. Leucocyte DNA was extracted and used
with 17 pairs of primers (details available upon
request) for polymerase chain reaction (PCR)
amplification of the 17 coding exons and adjoining
splice junctions of the HRPT2 gene, as previously
described [15]. The DNA sequences of gel purified PCR
products were determined [15]. Tumours, including
uterine specimens, were not available for the extrac-
tion of DNA to enable the identification of somatic
mutations or LOH involving chromosome 1q loci.
Histological analysis of uterine specimens
Thirty-one women from 13 HPT-JT kindreds (fam-
ilies K2, K5, K7, K8, K14, K16, K18, K21, K26,
K27, K29, K30 and K31) had a hysterectomy and
the reports of histological analysis of 15 uterine
specimens were obtained from 15 affected women
from nine of these HPT-JT kindreds (families K2, K5,
K7, K14, K21, K27, K29, K30 and K31). The
histological slides were not available for independent
review by a panel of pathologists, and the necessity
of relying on pathology reports from medical records
represents a limitation of this study. However,
histological slides of the uterus from one patient,
who was the proband in family K5 (Table 1), were
available, and two sections were stained immuno-
histochemically with CD10, smooth muscle actin,
desmin and MiB1 (Ki67) for an independent pathol-
ogy review by S.M., who was not aware of the first
report. The findings of the original report were
confirmed, thereby suggesting that the reliance of


















[reference]fHPT PTC JT RL UTc
K27g 7/5 0/0 11 0 6 1 3/4 5/5 1/4 Pancreatitis F2 [3]
K28g 5/0 0/0 5 0 3 0 0/0 3/3 0/0 [1, 25]
K29g 2/1 0/0 2 0 3 0 1/1 1/1 1/1 Prostate carcinoma K11689 [2]
K30g 2/3 2/0 4 0 2 0 2/2 3/3 2/2 Prostate carcinoma,
colon carcinoma
[26]




K32 1/1 0/0 2 0 1 0 0/0 1/1 1/1 This report
K33 2/1 0/0 2 1 0 0 n/a 0/0 1/1 This report
Total 20/16 2/0 29 3 19 1 11/12 14/14 8/14
aMales (M)/females (F).
bTumours: primary hyperparathyroidism (HPT), parathyroid carcinoma (PTC), ossifying jaw tumours (JT), renal lesions (RL) and uterine
abnormalities (UT). Individuals with PTC were not included in the HPT column. Data not available is indicated (n/a).
cUterine pathology (UT); affected or carrier adult women with menorrhagia (and/or) hysterectomy/total number of affected and carrier
adult women.
dAffected or carrier adult males (M) and females (F) with offspring/total number of married affected and carrier adults of relevant sex.
eOther features that were observed in only one to three patients within a family.
fKindreds from different reports have been given various numbers, and these are provided together with the appropriate reference.
gFamily data updated from previous reports.
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this study on the validity of the original pathology
reports was generally appropriate.
Statistical analysis




An analysis of the 1596 bp of the entire coding
region and 32 adjacent splice sites identified two
separate mutations in two of the four HPT-JT
kindreds. Thus, family K14 (Table 1) was found to
have a novel deletional-insertion at codon 669
(669delAT/insG), which leads to a frameshift enco-
ding 33 missense amino acids before encountering a
premature Stop at codon 256. Family K18 (Table 1)
was found to have a 2 bp insertion at codon 679
(679insAG), which has been previously reported in
four other unrelated patients and their families [13,
15, 17, 22, 23] and this is predicted to lead to a
frameshift encoding 27 missense amino acids before
encountering a premature Stop at codon 257.
Genotype–phenotype correlation analysis
Correlations between HRPT2 mutations and the
clinical manifestations of HPT-JT appear to be absent.
For example, the five unrelated patients and their
families with the 2 bp (AG) insertion at codon 679
reveal a wide range of HPT-JT-associated tumours
(Table 1); all the affected members had parathyroid
tumours but parathyroid carcinomas were only
observed in two kindreds (families K15 and K17);
whilst ossifying jaw fibromas were present only in a
member of family K16; and three members of family
K15 had renal abnormalities which were not present
in any of the other families. Moreover, uterine
abnormalities (see below) were detected only in
individuals from families K16 and K18. Thus, there
appears to be a lack of genotype–phenotype correla-
tion. In addition, a comparison of the phenotypic
manifestations in the 26 families with HRPT2
mutations (Table 1) and the seven families without
HRPT2 mutations (Table 2) revealed no differences.
Thus, a prediction for the presence or absence of an
HRPT2 mutation in a family based upon the clinical
manifestations of HPT-JT is not possible. Further-
more, nonpenetrance is observed in >30% of muta-
tion carriers, and is observed in 10 of the families
with known HRPT2 mutations (Table 1) and in one
family without an HRPT2 mutation (Table 2). This
high degree of nonpenetrance will need to be
considered carefully when providing genetic coun-
selling.
Uterine abnormalities
Clinical evaluation of family K18 revealed that four
of the five women with the HRPT2 mutation had
experienced menorrhagia-requiring hysterectomy. A
review of the clinical data available from this and 12
other HPT-JT families identified that 20 of 27 women
with HRPT2 mutations from nine families (Table 1),
and 11 of 12 women from four HPT-JT families in
whom HRPT2 mutations were not detected (Table 2)
had suffered from menorrhagia that required hys-
terectomy at an early age [mean (±SD) age ¼
35 years (±8), age range ¼ 23–55 years, in 23
women from whom data on age of hysterectomy
were available]. Histological analysis of the 15
uterine specimens available led to the identification
of benign uterine pathology as well as benign and
malignant uterine tumours (Table 3). These consis-
ted of two adenosarcomas (Fig. 2), five adenofibro-
mas, four leiomyomas, eight cases of extensive
adenomyosis and four cases of endometrial hyperpl-
asia. Interestingly, the uterine tumours appear to
have a common embryological origin from the
mesodermal Mullerian duct system. The affected
women in these families often had multiple miscar-
riages and were found to be significantly impaired in
their ability to have offspring when compared with
their unaffected female relatives (P < 0.001) and
also to their affected male relatives (P < 0.01)
(Table 4). A similar analysis of the affected men in
Table 3 Uterine pathology identified in 15 women affected with
hyperparathyroidism-jaw tumour (HPT-JT) syndrome






aSome women had more than one uterine pathology.
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these families revealed that their ability to reproduce
was not significantly different from that of their
unaffected male or female relatives (Table 4).
Discussion
Our analysis of HPT-JT families, which has revealed
an absence of genotype–phenotype correlation
together with a high degree of nonpenetrance, has
expanded the spectrum of HPT-JT-associated tu-
mours to include uterine tumours. In addition, our
results show that these uterine tumours likely
contribute to the decrease in reproductive fitness of
women affected with HPT-JT. These uterine tumours
are likely to harbour somatic mutations or LOH
involving the HRPT2 gene similar to that reported
for parathyroid tumours from HPT-JT patients [16,
17], and a study for these DNA abnormalities is
required once suitable uterine tumour specimens
become available.
The size of the HRPT2 gene, the absence of a
genotype–phenotype correlation together with an
absence of a ‘mutational hotspot’ will make the
implementation of mutational analysis in a diagnos-
tic and clinical setting arduous, time-consuming and
expensive. Nevertheless, diagnostic DNA testing for
HRPT2 mutations should be considered in patients
Fig. 2 Uterine histology from proband of family K5 (Table 1).
Medium power (·20) view of section from uterus including
endometrium. This reveals the typical features of a low-grade
Mullerian adenosarcoma, which include a stag-horn neoplastic,
benign gland, surrounded by condensed cellular, slightly atyp-
ical stroma with very few mitoses. There were also appearances
of a likely invasion to the inner half of the myometrium. The
immunoprofile (not shown) of the adenosarcoma revealed:
stromal positivity with CD10 that was more pronounced in the
cambium layer around the glands; a moderate proliferation
score with MiB1 staining, which was greater in the stromal
compartments; and a marked absence of smooth muscle. The
low mitotic count and the lack of marked atypia are the likely
results of the progestogen therapy that the patient had received.
However, the patient had no prior exposure to tamoxifen
therapy.
Table 4 Summary of reproductive
data from 198 individuals from 19
hyperparathyroidism-jaw tumour
(HPT-JT) kindreds












Males 49b,c 2b,c 43c 1c 95 1.2 : 1
Females 32a,b 12a,b 57a,d 2a,d 103 0.8 : 1
Total 83 14 105 3 198 0.9 : 1
Male : female 1.5 : 1 0.2 : 1 0.8 : 1 0 : 1
Reproductive data for adult married affected or mutation carrying individuals, and unaffected
individuals in 19 HPT-JT kindreds. The affected and carrier females were significantly less likely to
have offspring when compared with the unaffected females (aP < 0.001) and to the affected and
carrier males (bP < 0.01). In contrast, the affected and carrier males did not differ in their ability to
have offspring when compared with the unaffected males (cP ¼ 0.7), or to the unaffected females
(dP ¼ 0.9). P-values were calculated using the chi-square test. Updated data, which were available
for 11 kindreds (K2, 5, 7, 16, 18, 26–31, Tables 1 and 2) were pooled with the previously published
data [5, 10, 15, 18] from nine kindreds (K3, K8, K11, K20–K25, Tables 1 and 2) for this analysis.
An analysis utilizing only the updated data from the 11 kindreds yielded the same significant
outcomes. For affected individuals, who had offspring, the numbers of offspring per affected (carrier)
male and female in 81 individuals (47 males and 34 females) in 19 kindreds (K2, K3, K5, K7, K8,
K11, K16, K18, K20–K27 and K29–K31) from whom data were available, were 2.51 and 2.97,
respectively. Excluding the six Romany kindreds (K20–K25) who tended to have more children at
an earlier age, altered the numbers of offspring per affected male and female to 2.49 and 2.68,
respectively.
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with HPT-JT, FIHP and ‘nonfamilial’ parathyroid
carcinomas, as it is likely to help in their clinical
management and in the genetic counselling and
screening of their relatives. This genetic counselling
and screening should be extended to include second-
degree relatives of a patient as nonpenetrance can be
>30%. It is important to note that >20% of HPT-JT
families will not have mutations involving the coding
region and the adjacent splice junctions (Table 2).
These families may have mutations involving: the
promoter regions; the untranslated regions; the
alternate transcript that remains uncharacterized;
whole exon or gene deletions that may not be
detected by PCR or DNA sequence analysis; methy-
lation that may lead to gene silencing; or mutation in
a nearby unidentified linked gene. These HPT-JT
families that do not have coding region HRPT2
mutations cannot be clinically distinguished from
those HPT-JT families that have HRPT2 mutations.
The parathyroid, uterine and renal malignancies
that occur in HPT-JT patients indicate that screening
for such tumours is likely to result in an earlier
detection and hence intervention that will help to
reduce morbidity and mortality. Guidelines for regu-
lar screening for the development of HPT-JT-associ-
ated tumours are not available, and we therefore
suggest them (Table 5). These suggested guidelines
will need to be modified in the light of emerging and
future clinical and genetic data, and a notable
example of the former is our identification of the
association of uterine tumours in 13 HPT-JT families
(Table 4), which have been previously emphasized in
only one other HPT-JT family in which two sisters
had uterine adenomyomatous polyps [29]. These
uterine tumours significantly reduced the reproduc-
tive fitness of the women affected by HPT-JT
(Table 3) and an earlier detection of these uterine
abnormalities together with appropriate treatment
will not only help to reduce morbidity and mortality,
but also enhance the ability for such women to have
children. Indeed these uterine abnormalities may
partially explain the rarity of large HPT-JT kindreds,
and account for the difficulties of finding recombi-
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